A Phase 1b, Open-label, Multicenter, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of AG-181 in Subjects With Phenylketonuria
Latest Information Update: 02 Dec 2025
At a glance
- Drugs AG 181 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions
- Sponsors Agios Pharmaceuticals
Most Recent Events
- 02 Dec 2025 New trial record